Amid rising scrutiny of pharmacy benefit manager practices, the Pennsylvania state auditor is recommending several steps that lawmakers should take to clamp down on these controversial middlemen in hopes of controlling prescription drug costs.

The effort was prompted after Ohio recently ended contracts with two of the largest PBMs over pricing practices in the Medicaid program that cost the state tens of millions of dollars, a step that triggered increased interest among officials in other states over contracts and an alleged lack of transparency.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Flat fee pricing for reimbursing PBM’s …. Let’s try it for a year nationally and we’ll see how many billions every state will save. The transparency PBM’s have in their contracts are , ” Take our below net payments or don’t accept the
    thousands of patients you could have filled prescriptions for”
    If the PBM’s had nothing to hide,why would they not want the findings released? Am I the only one who sees this Ed?
    For those that believe theres a fire wall .. I have a bridge for sale !!!!!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy